Shah Chintan P, Moreb Jan S
Department of Medicine, Hematology Oncology Division, University of Florida, 1600 SW Archer Road, Gainesville, 32608, FL, USA.
Department of Medicine, Hematology Oncology Division, University of Florida, Gainesville, FL, USA.
Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719843435. doi: 10.1177/1753944719843435.
The emergence of various targeted anticancer agents has led us to uncharted territory secondary to their cardiotoxic potential with many burning questions, which in turn has led to the evolution of the cardio-oncology field. These targeted agents differ in their cardiovascular complication (CVC) potential even within the same class and it is very difficult to design screening tests that can predict CVCs. Moreover, there is a need for more research to answer many crucial questions, since these toxicities are unanticipated and can lead to poor overall survival of cancer patients. We still do not clearly understand the mechanism for such toxicity, risk factors, and natural history. A better understanding of the underlying risk factors and identification of biomarkers would help us develop protocols for appropriate monitoring strategies which in turn would help capture these toxicities at early stages. In this succinct review, we try to focus on CVC definition, summarize some published research, and point to areas of unmet need in this new field.
各种靶向抗癌药物的出现，因其潜在的心脏毒性，将我们带入了未知领域，引发了诸多亟待解决的问题，进而推动了心脏肿瘤学领域的发展。这些靶向药物即使在同一类别中，其引发心血管并发症（CVC）的可能性也存在差异，而且很难设计出能够预测CVC的筛查测试。此外，由于这些毒性难以预料且可能导致癌症患者总体生存率降低，因此需要开展更多研究来回答许多关键问题。我们仍不清楚此类毒性的机制、风险因素和自然病程。更好地理解潜在风险因素并识别生物标志物，将有助于我们制定适当的监测策略方案，进而有助于在早期阶段发现这些毒性。在这篇简要综述中，我们试图聚焦于CVC的定义，总结一些已发表的研究，并指出这一新兴领域中尚未满足的需求领域。
